The Week in Review: Oct 26 – Nov 2, 2018

Friday, Nov 2, 2018 News Recap: Report on the Pacific AIDS Network (PAN) 2018 Fall Conference in Kelowna The Pacific AIDS Network held its annual Fall Conference and AGM October 30-31 in Kelowna. HepCBC attended this year for the first time as a Full Member, due to changes in the PAN Constitution and Bylaws. New Bylaws included: PAN no longer requires its hepatitis C organizational members to offer HIV-related services. Aging and Viral Hepatitis ...

Potential markers identified for early detection and prevention of liver cancer

Liver cancer is the second leading cause of cancer-related mortality worldwide, claiming 700,000 lives each year. Most cases are discovered too late for a cure—but now a study offers hope of early detection, and targets for new treatments. Published in Frontiers in Cell and Developmental Biology, the results show a dramatic increase in expression of sugar-burning 'glycolytic' enzymes in precancerous cirrhotic livers. This increase is associated with a sign

Novel Biomarkers Predict Mortality in Hepatitis B-Associated Liver Failure

In patients with hepatitis B-associated acute-on-chronic liver failure, the plasma biomarkers sCD163 and neutrophil gelatinase-associated lipocalin (NGAL) are independently associated with short-term mortality, according to study results published in Hepatology Research. The researchers found that sCD163 and NGAL showed strong independent associations with 28-day mortality. However, they did not find a significant association between copeptin and short-te

The Week in Review: July 27 – August 24, 2018

Friday, August 24, 2018 News Recap: Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients. Chronic fatigue, mood alterations and cognitive impairment are frequent accessory symptoms of HCV-infection. Fatigue and mood alterations have also been observed in autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC), but not in hepatitis B vi...

New online calculator predicts clinical improvement in liver failure after Hep C treatment

Investigators formulated a five-factor metric known as the BE3A score that offers specialists a shared decision-making tool to predict potential improvements after treatment in patients with hepatitis C virus (HCV)-associated liver failure, as detailed in a new study published in Gastroenterology. The five factors in the BE3A score include body mass index (BMI), encephalopathy, ascites, and serum levels of both alanine aminotransferase (ALT) and albumin.

The Week in Review: January 12 – January 19, 2018

Friday, January 19, 2018 News Recap: Research & Discoveries: Blood test for early detection of 8 cancers looks promising. Scientists have developed a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. The test, called CancerSEEK, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests wer...

Blood test for early detection of 8 cancers looks promising

Test includes some of the most deadly cancers currently lacking screening tools. Scientists are reporting progress on a blood test to detect many types of cancer at an early stage, including some of the most deadly ones that lack screening tools now. Many groups are working on liquid biopsy tests, which look for DNA and other things that tumours shed into blood, to try to find cancer before it spreads, when chances of a cure are best. In a study Thu

Liver test to aid paracetamol overdose treatment

People who overdose on paracetamol (acetaminophen) could be helped by a blood test that shows immediately if they are going to suffer liver damage. Researchers in Edinburgh and Liverpool said the test would help doctors identify which patients arriving in hospital need more intensive treatment. The blood test detects levels of specific molecules in blood associated with liver damage. The three different molecules are called miR-122, HMGB1 and FL-K18

Singapore’s Restalyst develops new method to improve liver cancer diagnosis

SINGAPORE, Nov. 9, 2017 /PRNewswire/ -- Singapore biomedical firm Restalyst has developed a new algorithm to detect liver cancer more accurately, improving the sensitivity to 90%. The new methodology looks at three factors: membrane bound protein ERBB3, AFP (alpha fetoprotein) and age of patient. It will detect and identify liver cancer more effectively, and better distinguish liver cancer from chronic hepatitis condition. An AFP test is commonly used

The Week in Review: October 6 – October 13, 2017

Friday, October 13, 2017 News Recap: Research & Discoveries After an intense hunt, researchers at the Norwegian University of Science and Technology (NTNU) can now describe an important part of the disease's guerrilla tactics: how hepatitis C converts innocent cells into outright virus factories.  How hepatitis C hides in the body. Apparently, liver cancer can be caught at an early stage through a newly developed blood test, improving the odd...